Tag Archives: Batch release

NMPA Clears 49 Vaccine and Biologic Batches in Late August

Leave a reply

Beijing, Aug 30, 2026 — China’s National Medical Products Administration cleared 49 batches of biological products for market distribution during the week ended Aug 30, 2026, spanning vaccines, blood products, and diagnostic reagents from major domestic manufacturers and one imported supplier.

Batch Release Summary

CategoryKey ProductsNotable Manufacturers
Vaccines13-valent pneumococcal conjugate; ACYW135 meningococcal conjugate; A/C meningococcal conjugate; EV71 inactivated; hepatitis A live attenuated; rabies (Vero cell and human diploid cell); oral polio type I/III; pentavalent rotavirus; influenza subunit; DTaPCanSinoBIO; Chengdu Olymvax; Walvax; CAMS; Changchun Institute; Changchun Zhuoyi; Chengdu Kanghua; Beijing Institute; Merck Sharp & Dohme; Jiangsu Zhonghui Yuan Tong; Chengdu Institute
Blood ProductsHuman coagulation Factor VIII; human fibrinogenShanghai RAAS Blood Products
DiagnosticsSyphilis TRUST; syphilis TP antibody ELISA; HIV antibody ELISA; HIV antigen/antibody ELISAInTec Xiamen; Shanghai Kehua Bio-engineering

Market Impact Analysis

The batch release underscores steady supply chain momentum across China’s biological product sector heading into the autumn vaccination season. CanSinoBIO secured approvals for multiple conjugate vaccine batches, including its 13-valent pneumococcal vaccine and ACYW135 meningococcal vaccine, reinforcing the company’s position in China’s expanding pediatric and adolescent immunization market. The inclusion of Merck Sharp & Dohme’s imported pentavalent rotavirus vaccine batches highlights continued reliance on foreign suppliers for select pediatric vaccines despite domestic capacity expansion.

Shanghai RAAS maintained its dominance in the plasma-derived therapeutics segment with Factor VIII and fibrinogen batches cleared, ensuring continuity of care for hemophilia and coagulation disorder patients. The diagnostic reagent releases—covering syphilis and HIV screening—support routine clinical and blood bank testing demand.

Forward-Looking Statement

Industry analysts expect the weekly batch release cadence to accelerate through September as manufacturers ramp production ahead of the national immunization program’s autumn campaign and flu season procurement. The strong showing of conjugate vaccines from CanSinoBIO and meningococcal products from multiple suppliers suggests adequate inventory for school-entry vaccination drives. Blood product batch volumes remain consistent with historical patterns, though ongoing plasma collection constraints may limit significant supply expansion through year-end.-China Health Reform Pulse

Policy Source: https://www.nifdc.org.cn/directory/web/nifdc/xxgk/ggtzh/jwgk/shwzhppfgg/202609011454062187203.html

NMPA Releases 49 Biological Product Batches in Late August

Leave a reply

Beijing, Aug 30, 2026 — China’s National Medical Products Administration cleared 49 batches of biological products for market distribution during the week ended Aug 30, 2026, spanning vaccines, blood products, and diagnostic reagents from major domestic manufacturers and one imported supplier.

Batch Release Summary

CategoryKey ProductsNotable Manufacturers
Vaccines13-valent pneumococcal conjugate; ACYW135 meningococcal conjugate; A/C meningococcal conjugate; EV71 inactivated; hepatitis A live attenuated; rabies (Vero cell and human diploid cell); oral polio type I/III; pentavalent rotavirus; influenza subunit; DTaPCanSinoBIO; Chengdu Olymvax; Walvax; CAMS; Changchun Institute; Changchun Zhuoyi; Chengdu Kanghua; Beijing Institute; Merck Sharp & Dohme; Jiangsu Zhonghui Yuan Tong; Chengdu Institute
Blood ProductsHuman coagulation Factor VIII; human fibrinogenShanghai RAAS Blood Products
DiagnosticsSyphilis TRUST; syphilis TP antibody ELISA; HIV antibody ELISA; HIV antigen/antibody ELISAInTec Xiamen; Shanghai Kehua Bio-engineering

Market Impact Analysis

The batch release underscores steady supply chain momentum across China’s biological product sector heading into the autumn vaccination season. CanSinoBIO secured approvals for multiple conjugate vaccine batches, including its 13-valent pneumococcal vaccine and ACYW135 meningococcal vaccine, reinforcing the company’s position in China’s expanding pediatric and adolescent immunization market. The inclusion of Merck Sharp & Dohme’s imported pentavalent rotavirus vaccine batches highlights continued reliance on foreign suppliers for select pediatric vaccines despite domestic capacity expansion.

Shanghai RAAS maintained its dominance in the plasma-derived therapeutics segment with Factor VIII and fibrinogen batches cleared, ensuring continuity of care for hemophilia and coagulation disorder patients. The diagnostic reagent releases—covering syphilis and HIV screening—support routine clinical and blood bank testing demand.

Forward-Looking Statement

Industry analysts expect the weekly batch release cadence to accelerate through September as manufacturers ramp production ahead of the national immunization program’s autumn campaign and flu season procurement. The strong showing of conjugate vaccines from CanSinoBIO and meningococcal products from multiple suppliers suggests adequate inventory for school-entry vaccination drives. Blood product batch volumes remain consistent with historical patterns, though ongoing plasma collection constraints may limit significant supply expansion through year-end.-China Health Reform Pulse

Policy Source: https://www.nifdc.org.cn/directory/web/nifdc/xxgk/ggtzh/jwgk/shwzhppfgg/202609011454062187203.html

Policy Analysis and Guidance: China’s Adjusted Timeline for Influenza Vaccine Batch Release

Leave a reply

China’s National Medical Products Administration (NMPA) has issued a notice adjusting the timeline for influenza vaccine batch release from 60 to 45 working days. This move aims to enhance the efficiency of vaccine distribution and better protect public health.

Key Policy Highlights

  1. Timeline Adjustment
    • New Standard: The batch release timeline for influenza vaccines has been reduced to 45 working days.
    • Implementation: The adjustment applies to applications submitted after the notice’s publication. Applications submitted before the notice will continue under the original 60-day timeline.
  2. Regulatory Oversight
    • Provincial Supervision: Provincial drug administration bureaus are required to strengthen oversight of batch release institutions within their jurisdictions.
    • Quality Management: Emphasis on continuous improvement of quality management practices within batch release institutions.
  3. Process Optimization
    • Workflow Enhancement: The China National Institutes for Food and Drug Control and batch release institutions are urged to optimize workflows to meet the new timeline without compromising safety and quality standards.

Policy Orientation and Industry Implications
The adjusted batch release timeline reflects China’s strategic focus on:

  • Public Health Protection: Ensuring timely availability of influenza vaccines to protect public health.
  • Regulatory Efficiency: Streamlining regulatory processes to enhance the speed and effectiveness of vaccine distribution.
  • Industry Standards: Maintaining high standards for vaccine quality and safety while promoting industry-wide efficiency improvements.

Conclusion
China’s adjustment to the influenza vaccine batch release timeline demonstrates a commitment to balancing regulatory rigor with public health needs. This policy supports faster vaccine distribution without compromising on safety, setting a benchmark for global regulatory efficiency. Stakeholders in the vaccine industry should align with these updated guidelines to ensure compliance and contribute to public health goals.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20250402161126141.html